Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Stryker Corporation — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $17.8, while Stryker Corporation trades at $312.67 (market cap $120.60B). The key difference: Stryker Corporation pays a 1.12% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| QYLD | SYK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $18.52 | $403.53 |
52-Week Low | $16.46 | $282.58 |
Market Cap | — | $120.60B |
Enterprise Value | — | $132.36B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $17.66, down 0.84% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with RSI at oversold levels. Recent dividend payments of $0.18-$0.19 highlight its income focus, though news articles question long-term wealth erosion versus Nasdaq growth.
The outlook remains cautious due to covered-call strategy limitations during market rallies. Risks include NAV erosion and underperformance versus benchmarks. Income-focused investors may find value, but growth-oriented investors face significant upside capture constraints in bullish markets.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
